Nystatin A3 is a lipid of Polyketides (PK) class. Nystatin a3 is associated with abnormalities such as Mycoses, Candidiasis of the genitals and Gigantism. The involved functions are known as Drug Interactions, Process, Synthesis, Fermentation and Anabolism. Nystatin a3 often locates in Cell membrane, Membrane, Protoplasm, Entire oral cavity and integral to membrane. The associated genes with Nystatin A3 are Gene Clusters. The related lipids are Sterols, 1,2-oleoylphosphatidylcholine, Membrane Lipids, DOPE and N-caproylsphingosine.
To understand associated biological information of Nystatin A3, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Nystatin A3 is suspected in Mycoses, Candidiasis of the genitals, Gigantism and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Nystatin A3
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Wittekamp BH et al. | Nystatin versus amphotericin B to prevent and eradicate Candida colonization during selective digestive tract decontamination in critically ill patients. | 2015 | Intensive Care Med | pmid:26459880 |
Chen Y et al. | Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration. | 2015 | Int. J. Cancer | pmid:24798787 |
Sasek V | Consequences of Misnomer or Mistakes in Identification of Fungal Species. | 2015 | Int J Med Mushrooms | pmid:26853957 |
Guerra CM et al. | Duration of prophylaxis against fungal infection in kidney transplant recipients. | 2015 | Prog Transplant | pmid:26645924 |
Austin N et al. | Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. | 2015 | Cochrane Database Syst Rev | pmid:26497202 |
Tamura M et al. | Involvement of an intracellular vesicular transport process in naked-sgRNA-mediated TRUE gene silencing. | 2015 | Mol Med Rep | pmid:26238202 |
Bassi P and Kaur G | Bioadhesive vaginal drug delivery of nystatin using a derivatized polymer: Development and characterization. | 2015 | Eur J Pharm Biopharm | pmid:26235393 |
Fan S et al. | Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. | 2015 | Mycopathologia | pmid:25416649 |
Zhu Y et al. | Candida parapsilosis sensu stricto and the closely related species Candida orthopsilosis and Candida metapsilosis in vulvovaginal candidiasis. | 2015 | Mycopathologia | pmid:25322705 |
Oncel MY et al. | Comparison of Lactobacillus reuteri and nystatin prophylaxis on Candida colonization and infection in very low birth weight infants. | 2015 | J. Matern. Fetal. Neonatal. Med. | pmid:25245226 |